- Home
- KIND vs IKT Comparison
KIND vs IKT Comparison
Compare KIND & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- IKT
- Stock Information
- Founded
- KIND 2011
- IKT 2008
- Country
- KIND United States
- IKT United States
- Employees
- KIND N/A
- IKT N/A
- Industry
- KIND Computer Software: Programming Data Processing
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- IKT Health Care
- Exchange
- KIND Nasdaq
- IKT Nasdaq
- Market Cap
- KIND 974.5M
- IKT 159.2M
- IPO Year
- KIND N/A
- IKT 2020
- Fundamental
- Price
- KIND $2.42
- IKT $3.42
- Analyst Decision
- KIND Hold
- IKT Strong Buy
- Analyst Count
- KIND 2
- IKT 2
- Target Price
- KIND $2.75
- IKT $6.50
- AVG Volume (30 Days)
- KIND 2.3M
- IKT 450.8K
- Earning Date
- KIND 11-06-2024
- IKT 11-14-2024
- Dividend Yield
- KIND N/A
- IKT N/A
- EPS Growth
- KIND N/A
- IKT N/A
- EPS
- KIND N/A
- IKT N/A
- Revenue
- KIND $237,605,000.00
- IKT $1.00
- Revenue This Year
- KIND $14.90
- IKT N/A
- Revenue Next Year
- KIND $14.61
- IKT N/A
- P/E Ratio
- KIND N/A
- IKT N/A
- Revenue Growth
- KIND 9.99
- IKT N/A
- 52 Week Low
- KIND $1.32
- IKT $1.12
- 52 Week High
- KIND $3.00
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- KIND 41.53
- IKT 52.41
- Support Level
- KIND $2.26
- IKT $3.12
- Resistance Level
- KIND $2.68
- IKT $4.20
- Average True Range (ATR)
- KIND 0.13
- IKT 0.42
- MACD
- KIND -0.03
- IKT -0.00
- Stochastic Oscillator
- KIND 16.04
- IKT 30.67
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.